Clinical Trial Update: Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance [Phase 2]

View source ↗

Summary

Phase 2 trial investigating lenalidomide for neuropathy associated with nonmalignant MGUS; study terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy of Undetermined Significance
• Neuropathy

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Neuropathy, Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS) | Phase 2 | Status: TERMINATED | Results posted: 2018-09-11